Compare JUBILANT LIFE SCIENCES with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES VENUS REMEDIES JUBILANT LIFE SCIENCES/
VENUS REMEDIES
 
P/E (TTM) x 14.4 -5.1 - View Chart
P/BV x 2.7 0.3 797.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   VENUS REMEDIES
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
VENUS REMEDIES
Mar-18
JUBILANT LIFE SCIENCES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs898126 713.3%   
Low Rs61861 1,010.6%   
Sales per share (Unadj.) Rs572.0301.8 189.5%  
Earnings per share (Unadj.) Rs36.2-24.9 -145.7%  
Cash flow per share (Unadj.) Rs59.52.5 2,338.8%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.9293.3 102.9%  
Shares outstanding (eoy) m159.2812.34 1,290.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 427.6%   
Avg P/E ratio x20.9-3.8 -556.4%  
P/CF ratio (eoy) x12.736.7 34.7%  
Price / Book Value ratio x2.50.3 787.3%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,6941,154 10,460.7%   
No. of employees `0002.40.9 258.4%   
Total wages/salary Rs m19,260393 4,899.4%   
Avg. sales/employee Rs Th38,120.64,026.1 946.8%   
Avg. wages/employee Rs Th8,058.4425.0 1,896.2%   
Avg. net profit/employee Rs Th2,414.3-331.8 -727.7%   
INCOME DATA
Net Sales Rs m91,1083,724 2,446.4%  
Other income Rs m35723 1,588.4%   
Total revenues Rs m91,4663,747 2,441.3%   
Gross profit Rs m17,390395 4,404.8%  
Depreciation Rs m3,709338 1,096.4%   
Interest Rs m2,198354 620.4%   
Profit before tax Rs m11,840-275 -4,300.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,26832 10,341.8%   
Profit after tax Rs m5,770-307 -1,880.1%  
Gross profit margin %19.110.6 180.0%  
Effective tax rate %27.6-11.5 -240.5%   
Net profit margin %6.3-8.2 -76.9%  
BALANCE SHEET DATA
Current assets Rs m45,8482,638 1,738.2%   
Current liabilities Rs m20,8972,305 906.7%   
Net working cap to sales %27.48.9 306.2%  
Current ratio x2.21.1 191.7%  
Inventory Days Days57135 41.9%  
Debtors Days Days5146 110.0%  
Net fixed assets Rs m65,4984,871 1,344.7%   
Share capital Rs m159123 129.1%   
"Free" reserves Rs m47,9303,496 1,371.1%   
Net worth Rs m48,0893,619 1,328.8%   
Long term debt Rs m42,4291,374 3,087.1%   
Total assets Rs m114,6857,509 1,527.4%  
Interest coverage x6.40.2 2,864.3%   
Debt to equity ratio x0.90.4 232.3%  
Sales to assets ratio x0.80.5 160.2%   
Return on assets %6.90.6 1,100.6%  
Return on equity %12.0-8.5 -141.5%  
Return on capital %12.41.6 784.6%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m12,4220-   
Fx outflow Rs m17,227517 3,335.3%   
Net fx Rs m-4,805-517 930.3%   
CASH FLOW
From Operations Rs m11,215514 2,180.2%  
From Investments Rs m-10,118-123 8,219.7%  
From Financial Activity Rs m6,574-387 -1,698.3%  
Net Cashflow Rs m7,6124 181,242.9%  

Share Holding

Indian Promoters % 45.6 32.9 138.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 0.2 4,833.3%  
FIIs % 21.2 0.6 3,655.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 66.4 31.8%  
Shareholders   23,815 20,121 118.4%  
Pledged promoter(s) holding % 15.9 36.4 43.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Healthcare and Metal Stocks Witness Selling(Closing)

After staging a gap-down opening, Indian share markets recovered losses as the session progressed and ended on a flat note.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 12, 2020 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS